Quality assessment of Chinese clinical practice guidelines of primary hepatic carcinoma from 2016 to 2017_Chinese Journal of Evidence-Based Medicine

Authors：

LI Qin ,  LIU Fei , WEI Yonggang , LI Bo

Division of Liver Transplantation, Department of Liver and Vascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding?author：

LIU Fei, Email: zhuzhongfen@163.com

Keywords：

Primary hepatic carcinoma; Clinical practice guideline; Consensus; Quality assessment; AGREE Ⅱ

DOI：

10.7507/1672-2531.201804143

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To assess the quality of clinical practice guidelines for primary hepatic carcinoma published in 2016 and 2017 in China. Methods CNKI, WanFang Data, CBM and VIP databases were searched for clinical practice guidelines for primary hepatic carcinoma in China. The search date was from Jan. 1^st, 2016 to Jan. 1^st, 2018. Four researchers independently selected literatures and extracted data according to the inclusion and exclusion criteria. The Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ) was utilized to assess the methodological quality of the guidelines. Results A total of 7 guidelines were included. The average scores of six domains for these guidelines were: 65.1% for scope and purpose, 39.4% for stakeholders’ involvement, 64.3% for rigor of development, 55.6% for clarity of presentation, 61.8% for applicability and 6.1% for editorial independence. Conclusions The quality of clinical practice guidelines for primary hepatic carcinoma in China is relative high, of which the recommendations are of great value in clinical practice, yet still required to be improved in some ways.

Citation： LI Qin, LIU Fei, WEI Yonggang, LI Bo. Quality assessment of Chinese clinical practice guidelines of primary hepatic carcinoma from 2016 to 2017. Chinese Journal of Evidence-Based Medicine, 2018, 18(10): 1109-1113. doi: 10.7507/1672-2531.201804143 Copy

1.	Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (Baltimore, Md), 2013, 58(1): 98-107.
2.	Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol, 2012, 56(6): 1330-1335.
3.	Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol, 2012, 107(4): 569-577.
4.	Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol, 2012, 57(4): 821-829.
5.	陳丹丹, 劉媛, 姬旭慧, 等. 原發性肝癌發病影響因素的病例對照研究. 鄭州大學學報 (醫學版), 2013, 48(2): 249-253.
6.	相迪, 戴建國. 原發性肝癌的綜合治療研究進展. 山東醫藥, 2017, 57(20): 111-112.
7.	Graham R, Mancher M, Miller Wolman D, et al. Clinical Practice Guidelines We Can Trust. Port J Nephrol Hypert, 2011: 1-13.
8.	Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J, 2010, 182(18): E839-E842.
9.	謝利民, 王文岳. 《臨床指南研究與評價系統Ⅱ》簡介. 中西醫結合學報, 2012, 10(2): 160-165.
10.	中華人民共和國衛生和計劃生育委員會醫政醫管局. 原發性肝癌診療規范 (2017 年版). 中華消化外科雜志, 2017, 16(7): 635-647.
11.	高春芳, 房萌, 季君, 等. 多學科甲胎蛋白異質體臨床應用專家共識. 診斷學理論與實踐, 2018, 17(1): 19-24.
12.	程樹群, 楊甲梅, 沈鋒, 等. 肝細胞癌合并門靜脈癌栓多學科診治——東方肝膽外科醫院專家共識. 中華肝膽外科雜志, 2015, 21(9): 582-590.
13.	鄭加生, 范衛君, 胡凱文, 等. 影像引導肝臟腫瘤熱消融治療技術臨床規范化應用專家共識. 臨床肝膽病雜志, 2017, 33(10): 1864-1869.
14.	中華醫學會放射腫瘤學分會, 中國生物醫學工程學會精確放療分會肝癌學組與消化系統腫瘤專家委員會, 中國研究型醫院學會放射腫瘤學分會肝癌學組. 2016 年原發性肝癌放療共識. 中華放射腫瘤學雜志, 2016, (11): 1141-1150.
15.	陳亞進, 曹軍. 肝臟及膽道惡性腫瘤多學科綜合治療協作組診療模式專家共識. 中國實用外科雜志, 2017, 33(10): 1864-1869.
16.	中國醫師協會介入醫師分會. 注射用洛鉑在原發性肝癌 TACE 治療中的專家共識 (2016 版). 中華介入放射學電子雜志, 2016, 4(1): 1-3.
17.	陳輝, 范衛君, 胡凱文, 等. 基于 AGREE Ⅱ的闌尾炎臨床實踐指南質量評價研究. 重慶醫科大學學報, 2015, 40(10): 1280-1284.
18.	江梅, 廖理粵, 羅煒, 等. 國內咳嗽診療指南的質量評價. 中國循證醫學雜志, 2015, 15(4): 409-413.
19.	李楠, 姚亮, 吳瓊芳, 等. 2012~2013 年中國大陸期刊發表臨床實踐指南質量評價. 中國循證醫學雜志, 2015, 15(3): 259-263.
20.	EASL Clinical Practice Guidelines:. Management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182-236.
21.	張鳴明, 劉鳴. 循證醫學的概念和起源. 華西醫學, 1998, 13(3): 265.
22.	Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ, 1996, 312(7023): 71-72.
23.	Chow PK, Choo SP, Ng DC, et al. National cancer centre singapore consensus guidelines for hepatocellular carcinoma. Liver Cancer, 2016, 5(2): 97-106.
24.	Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017, 11(4): 1-54.
25.	Ahn JH, An C, Choi JY, et al. Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the Korean society of abdominal radiology. Korean J Radiol, 2017, 18(3): 427-443.
26.	Cheung TT, Han HS, She WH, et al. The Asia pacific consensus statement on laparoscopic liver resection for hepatocellular carcinoma: a report from the 7th Asia-pacific primary liver cancer expert meeting held in Hongkong. Liver Cancer, 2018, 7(1): 28-39.
27.	Heimbach J, Kulik L M, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2017, 67(1): 358-380.

1. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (Baltimore, Md), 2013, 58(1): 98-107.
2. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol, 2012, 56(6): 1330-1335.
3. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol, 2012, 107(4): 569-577.
4. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol, 2012, 57(4): 821-829.
5. 陳丹丹, 劉媛, 姬旭慧, 等. 原發性肝癌發病影響因素的病例對照研究. 鄭州大學學報 (醫學版), 2013, 48(2): 249-253.
6. 相迪, 戴建國. 原發性肝癌的綜合治療研究進展. 山東醫藥, 2017, 57(20): 111-112.
7. Graham R, Mancher M, Miller Wolman D, et al. Clinical Practice Guidelines We Can Trust. Port J Nephrol Hypert, 2011: 1-13.
8. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J, 2010, 182(18): E839-E842.
9. 謝利民, 王文岳. 《臨床指南研究與評價系統Ⅱ》簡介. 中西醫結合學報, 2012, 10(2): 160-165.
10. 中華人民共和國衛生和計劃生育委員會醫政醫管局. 原發性肝癌診療規范 (2017 年版). 中華消化外科雜志, 2017, 16(7): 635-647.
11. 高春芳, 房萌, 季君, 等. 多學科甲胎蛋白異質體臨床應用專家共識. 診斷學理論與實踐, 2018, 17(1): 19-24.
12. 程樹群, 楊甲梅, 沈鋒, 等. 肝細胞癌合并門靜脈癌栓多學科診治——東方肝膽外科醫院專家共識. 中華肝膽外科雜志, 2015, 21(9): 582-590.
13. 鄭加生, 范衛君, 胡凱文, 等. 影像引導肝臟腫瘤熱消融治療技術臨床規范化應用專家共識. 臨床肝膽病雜志, 2017, 33(10): 1864-1869.
14. 中華醫學會放射腫瘤學分會, 中國生物醫學工程學會精確放療分會肝癌學組與消化系統腫瘤專家委員會, 中國研究型醫院學會放射腫瘤學分會肝癌學組. 2016 年原發性肝癌放療共識. 中華放射腫瘤學雜志, 2016, (11): 1141-1150.
15. 陳亞進, 曹軍. 肝臟及膽道惡性腫瘤多學科綜合治療協作組診療模式專家共識. 中國實用外科雜志, 2017, 33(10): 1864-1869.
16. 中國醫師協會介入醫師分會. 注射用洛鉑在原發性肝癌 TACE 治療中的專家共識 (2016 版). 中華介入放射學電子雜志, 2016, 4(1): 1-3.
17. 陳輝, 范衛君, 胡凱文, 等. 基于 AGREE Ⅱ的闌尾炎臨床實踐指南質量評價研究. 重慶醫科大學學報, 2015, 40(10): 1280-1284.
18. 江梅, 廖理粵, 羅煒, 等. 國內咳嗽診療指南的質量評價. 中國循證醫學雜志, 2015, 15(4): 409-413.
19. 李楠, 姚亮, 吳瓊芳, 等. 2012~2013 年中國大陸期刊發表臨床實踐指南質量評價. 中國循證醫學雜志, 2015, 15(3): 259-263.
20. EASL Clinical Practice Guidelines:. Management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182-236.
21. 張鳴明, 劉鳴. 循證醫學的概念和起源. 華西醫學, 1998, 13(3): 265.
22. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ, 1996, 312(7023): 71-72.
23. Chow PK, Choo SP, Ng DC, et al. National cancer centre singapore consensus guidelines for hepatocellular carcinoma. Liver Cancer, 2016, 5(2): 97-106.
24. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017, 11(4): 1-54.
25. Ahn JH, An C, Choi JY, et al. Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the Korean society of abdominal radiology. Korean J Radiol, 2017, 18(3): 427-443.
26. Cheung TT, Han HS, She WH, et al. The Asia pacific consensus statement on laparoscopic liver resection for hepatocellular carcinoma: a report from the 7th Asia-pacific primary liver cancer expert meeting held in Hongkong. Liver Cancer, 2018, 7(1): 28-39.
27. Heimbach J, Kulik L M, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2017, 67(1): 358-380.

Chinese Journal of Evidence-Based Medicine

Quality assessment of Chinese clinical practice guidelines of primary hepatic carcinoma from 2016 to 2017

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content